Xeroderma pigmentosum group D gene Gastric cancer Radiotherapy
Zarate RN, Arias F, Bandres E, Cubedo E, Malumbres R, Garcia-Foncillas J. Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy. World J Gastroenterol 2006 Oct 7;12(37):6032-6036.
AIM: To evaluate the potential association of xeroderma
pigmentosum group D (XPD) codon 751 variant with
outcome after chemo-radiotherapy in patients with
resected gastric cancer.
METHODS: We used PCR-RFLP to evaluate the genetic
XPD Lys751Gln polymorphisms in 44 patients with stage
III (48%) and IV (20%) gastric cancer treated with
surgery following radiation therapy plus 5-fluorouracil/
leucovorin based chemotherapy.
RESULTS: Statistical analysis showed that 75% (12 of
16) of relapse patients showed Lys /Lys genotype more
frequently (P = 0.042). The Lys polymorphism was an
independent predictor of high-risk relapse-free survival
from Cox analysis (HR: 3.07, 95% CI: 1.07-8.78, P =
0.036) and Kaplan-Meir test (P = 0.027, log-rank test).
CONCLUSION: XPD Lys751Gln polymorphism may be
an important marker in the prediction of clinical outcome
to chemo-radiotherapy in resected gastric cancer